The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation: An Individual Patient Meta-analysis
Abstract
CONTEXT: Patients with nonvalvular atrial fibrillation (AF) have an increased risk of stroke and other vascular events. OBJECTIVE: To compare the risk of vascular and bleeding events in patients with nonvalvular AF treated with vitamin K -inhibiting oral anticoagulants or acetylsalicylic acid (aspirin). DESIGN: Pooled analysis of patient-level data from 6 published, randomized clinical trials. PATIENTS: A total of 4052 patients with AF randomly assigned to receive therapeutic doses of oral anticoagulant or aspirin with or without low-dose oral anticoagulants. MAIN OUTCOME MEASURES: Ischemic and hemorrhagic stroke, other cardiovascular events, all-cause death, and major bleeding events. Person-year incidence rates were calculated to provide crude comparisons. Relative efficacy was assessed using proportional hazards modeling stratified by study. The variation of the oral anticoagulant's relative effect by pertinent patient factors was explored with interaction terms. All analyses were conducted using the intention-to-treat principle. RESULTS: Patients receiving oral anticoagulant and aspirin were balanced for important prognostic factors. There was no significant heterogeneity between trials in the relative efficacy of oral anticoagulant vs aspirin for any outcome. Patients receiving oral anticoagulant were significantly less likely to experience any stroke (2.4 vs 4.5 events per 100 patient-years; hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.43-0.71), ischemic stroke (HR, 0.48; 95% CI, 0.37-0.63), or cardiovascular events (HR, 0.71; 95% CI, 0.59-0.85) but were more likely to experience major bleeding (2.2 vs 1.3 events per 100 patient-years; HR, 1.71; 95% CI, 1.21-2.41). The reduction in ischemic stroke risk was similar in patients with paroxysmal AF (1.5 vs 4.7 events per 100 patient-years; HR, 0.32; 95% CI, 0.16-0.61; P<.001). Treating 1000 patients with AF for 1 year with oral anticoagulant rather than aspirin would prevent 23 ischemic strokes while causing 9 additional major bleeds. Overall all-cause survival did not differ but appeared to improve for oral anticoagulant patients 3 years after therapy was started. CONCLUSIONS: Compared with aspirin, oral anticoagulant significantly decreases the risk of all strokes, ischemic strokes, and cardiovascular events for patients with nonvalvular chronic or paroxysmal AF but modestly increases the absolute risk of major bleeding. The balance of benefits and risks varies by patient subgroup.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Petersen, P., Godtfredsen, J., Boysen, G., Andersen, E., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,820
Self-citationEAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,741
Stroke Prevention in Atrial Fibrillation Study. Final results.
(1991) · Circulation · doi:10.1161/01.cir.84.2.527 · Cited by 1,696
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis
Hart, R. G., Benavente, O., McBride, R., & Pearce, L. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-7-199910050-00003 · Cited by 1,638
Self-citation(1990) · New England Journal of Medicine · doi:10.1056/nejm199011293232201 · Cited by 1,530
Forbes, C., & Collaborators, E. (1997) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1997.tb11433.x · Cited by 1,411
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L. E., Asinger, R. W., Cannom, D. S., Crijns, H. J., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,348
Canadian atrial fibrillation anticoaguiation (CAFA) study
Connolly, S. J., Laupacis, A., Gent, M., Roberts, R. S., Cairns, J. A., & Joyner, C. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90585-w · Cited by 1,111
Self-citationWarfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280227 · Cited by 1,067
Devereaux, P. J., Fahey, T., Anderson, D. R., Gardner, M. J., Putnam, W., Flowerdew, G. J., Brownell, B. F., Nagpal, S., & Cox, J. L. (2001) · BMJ · doi:10.1136/bmj.323.7323.1218 · Cited by 421
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community
Sudlow, M., Thomson, R., Thwaites, B., Rodgers, H., & Kenny, R. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01401-9 · Cited by 383
Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis
Takkouche, B., Cadarso-Suarez, C., & Spiegelman, D. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009981 · Cited by 380 · cited 1×
“We assessed heterogeneity between studies for each outcome by visually comparing HRs for each study with the overall estimate and by calculating the DerSimonian and Laird Q statistic for heterogeneity.(50) To measure interactions between treatment group and baseline factors, appropriate interaction terms were included…”
MethodThe Effect of Stroke and Stroke Prophylaxis With Aspirin or Warfarin on Quality of Life
Gage, B. F. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.16.1829 · Cited by 370
Atrial Fibrillation and Stroke: Concepts and Controversies
Hart, R. G., & Halperin, J. L. (2001) · Stroke · doi:10.1161/01.str.32.3.803 · Cited by 318
Self-citationGulløv, A. L., Koefoed, B. G., Petersen, P., Pedersen, T. S., Andersen, E. D., Godtfredsen, J., & Boysen, G. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.14.1513 · Cited by 301
Self-citationBleeding During Antithrombotic Therapy in Patients With Atrial Fibrillation
(1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440040081009 · Cited by 283
Ezekowitz (1992) · New England Journal of Medicine · Cited by 266
Antithrombotic Therapy in Atrial Fibrillation
Dunn, M., Alexander, J., de Silva, R., & Hildner, F. (1989) · Chest · doi:10.1378/chest.95.2_supplement.118s · Cited by 264
Aguilar, M. I., & Hart, R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001927.pub2 · Cited by 252
Self-citationHellemons, B. S. P., Langenberg, M., Lodder, J., Vermeer, F., Schouten, H. J. A., Lemmens, T., van Ree, J. W., & Knottnerus, J. A. (1999) · BMJ · doi:10.1136/bmj.319.7215.958 · Cited by 226
Self-citationGottlieb, L. K. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420170093009 · Cited by 224
Patient preferences for stroke outcomes.
Solomon, N. A., Glick, H. A., Russo, C. J., Lee, J., & Schulman, K. A. (1994) · Stroke · doi:10.1161/01.str.25.9.1721 · Cited by 202
Morocutti, C., Amabile, G., Fattapposta, F., Nicolosi, A., Matteoli, S., Trappolini, M., Cataldo, G., Milanesi, G., Lavezzari, M., Pamparana, F., et al. (1997) · Stroke · doi:10.1161/01.str.28.5.1015 · Cited by 200
Cheung, R. (1998) · The HKU Scholars Hub (University of Hong Kong) · Cited by 189
Atrial fibrillation and stroke. Three new studies, three remaining questions
Albers, G. W. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.13.1443 · Cited by 182
Preventing Stroke in Patients With Atrial Fibrillation
Ezekowitz, M. D. (1999) · JAMA · doi:10.1001/jama.281.19.1830 · Cited by 169
Prevention of stroke in patients with nonvalvular atrial fibrillation
Hart, R. G., Sherman, D. G., Easton, J. D., & Cairns, J. A. (1998) · Neurology · doi:10.1212/wnl.51.3.674 · Cited by 164
Self-citationSaxena, R. R., & Koudstaal, P. J. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000185.pub2 · Cited by 150
Self-citationCox Proportional Hazards Regression Model
Harrell, F. E. (2015) · Springer series in statistics · doi:10.1007/978-3-319-19425-7_20 · Cited by 142
Evans, A., & Kalra, L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1443 · Cited by 134
Taylor, F. C., Cohen, H., & Ebrahim, S. B. J. (2001) · BMJ · doi:10.1136/bmj.322.7282.321 · Cited by 126
Warfarin for Atrial Fibrillation: The Patient's Perspective
Man‐Son‐Hing, M., Laupacis, A., O'Connor, A., Wells, G., Lemelin, J., Wood, W., & Dermer, M. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.16.1841 · Cited by 117
Self-citationPengo, V., Zasso, A., Barbero, F., Banzato, A., Nante, G., Parissenti, L., John, N., Noventa, F., & Volta, S. D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00357-9 · Cited by 109
Alternate-day dosing of aspirin in atrial fibrillation
Posada, I. S., & Barriales, V. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70259-0 · Cited by 101
Stroke prevention in nonvalvular atrial fibrillation: A review of prospective randomized trials
Albers, G. W., Sherman, D. G., Gress, D. R., Paulseth, J. E., & Petersen, P. (1991) · Annals of Neurology · doi:10.1002/ana.410300402 · Cited by 101
Self-citationStroke Prevention in Nonvalvular Atrial Fibrillation
Albers, G. W., Atwood, J. E., Hirsh, J., Sherman, D. G., Hughes, R. A., & Connolly, S. J. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-727 · Cited by 78
Self-citationAnticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter
Segal, J. B., McNamara, R. L., Miller, M. R., Powe, N. R., Goodman, S. N., Robinson, K. A., & Bass, E. B. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001938.pub2 · Cited by 50
Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis.
Green, C. J., Hadorn, D. C., Bassett, K. L., & Kazanjian, A. (1997) · PubMed · Cited by 29
Choice of Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation
Albers, G. W. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.14.1487 · Cited by 24
Howard, P. A., & Duncan, P. W. (1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703101012 · Cited by 18
Atrial fibrillation, stroke and anticoagulation
Kitchens, J. M., & Flegel, K. M. (1986) · Journal of General Internal Medicine · doi:10.1007/bf02599816 · Cited by 14
Cited by
Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182009701 · Cited by 6,149
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
“Data derived from Hart et al(136,137) and van Walraven et al.(138) Stroke includes both ischemic and hemorrhagic stroke.”
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191259 · Cited by 3,908
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191261 · Cited by 3,140
Metadata
- Authors
- van Walraven, C., Hart, R. G., Singer, D. E., Laupacis, A., Connolly, S., Petersen, P., Koudstaal, P. J., Chang, Y., & Hellemons, B.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-11-20
- Volume
- 288
- Issue
- 19
- Pages
- 2441
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2045913143
- Cited by
- 714
- References
- 44
- FWCI
- 21.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.